CD8A and neoplasm: Under TGF-β and IL-2 signaling, the transcription factor BCL6 antagonizes PRDM1, inhibiting the transition of TPEX cells to a TEX phenotype and enhancing CD8+ T cell-mediated anti-tumor immunity during anti-PD-1 therapy [27].